|Nasdaq:||GOOG NFLX AMZN BIIB IBB TSLA ILMN ALXN AMGN COST FFIV TRIP SBAC PCYC WDC VRTX AAPL SNDK BEAV|
|Nyse:||PXD V ACT IVV IBM GS SPG AGN LMT LNKD PRGO FDX TWC XEC MMM CVX BA NOC TMO|
|New Highs:||SHW IVV SPG LMT XEC PII APD CVX FLT NOC GD NSC SIAL UNP HES AAPL APH CI AMT MCO|
Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization therapeutic products for the treatment for cardiovascular diseases in the United States. It develops products in the areas of lipid science and therapeutic benefits of polyunsaturated fatty acids. The company markets Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. It is also developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. The company was formerly known as Ethical Holdings plc. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland.